Navigation Links
OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
Date:9/23/2009

SEATTLE, Sept. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that data from a Phase II study from Brown University of OPAXIO(TM) (paclitaxel poliglumex) combined with standard cisplatin and concurrent radiation in patients with advanced esophageal cancer will be presented by Dr. Howard Safran in an oral Proffered Papers session at the Annual Meeting of the International Society of Gastrointestinal Oncology in Philadelphia, Pennsylvania on Thursday, October 1st at 2:35 p.m. (Eastern time).

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434
    E: deramian@ctiseattle.com
    www.celltherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.celltherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
2. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
3. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
4. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
5. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
8. ANAVEX completes scale-up manufacturing of ANAVEX 2-73 for Phase I Alzheimers disease clinical trials
9. Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
10. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
11. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
(Date:9/13/2017)... ATLANTA , Sept. 13, 2017   OrthoAtlanta ... to the Atlanta Football Host Committee (AFHC) for the 2018 ... Monday, Jan. 8, 2018, at Mercedes-Benz Stadium in ... part of the AFHC "I,m In" campaign, participating in many ... ...
(Date:9/9/2017)... Sept. 8, 2017 Dealmed Medical Supplies, ... of medical equipment, supplies, drugs, vaccines, and specialty medical ... into an agreement to acquire Vantage Medical Supplies, a ... Holtsville, New York . ... new and emerging medical practices, will operate under the ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... Introducing Panther, the revolutionary new iPhone case ... platform Kickstarter seeking support for the #WarOnGrime. , Fact: iPhones are 18 ... shockingly revolting, yet true. The Panther iPhone cases are the first weapon in the ...
(Date:9/25/2017)... ... ... Tim Rial Agency of Burleson, TX announces the creation of a philanthropic program ... groups and community leaders, the agency hopes to bring greater awareness to important local ... , Tim Rial, the owner of Tim Rial Agency, has chosen to debut ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... Portable, Continuous, Miniature, and Modular (PCMM) collaboration with Pfizer and GEA by designing ... Dosage line. The new PODs will provide tablet coating capability in the existing ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... ... host of the nationally syndicated The Sharon Kleyne Hour Power of Water, Global ... like us to shift our Olympic focus from a once-every-four-years series of events ...
(Date:9/25/2017)... ... September 25, 2017 , ... METTLER TOLEDO is pleased to host ... in Los Angeles, CA. The symposium will feature speakers from North American National Measurement ... calibration technologies and help with planning for the future of the modern lab. , ...
Breaking Medicine News(10 mins):